Jubilant Pharmova Limited (JUBLPHARMA.BO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Arvind Chokhany | Group CFO & Whole-Time Director | 53.43M | -- | 1972 |
| Laxshmivarahan Ramasubramani | Group Chief Digital & Information Officer | -- | -- | 1978 |
| Mr. Naresh Kapoor | Company Secretary & Compliance Officer | 6.86M | -- | 1974 |
| Mr. Praveen Kumar Gupta B.Com, B.Com., Ca, Cs, F.C.A. | Executive VP & Head of Direct Taxation | -- | -- | 1974 |
| Mr. K.V.S Satish Kumar | Chief Sustainability Officer | -- | -- | 1977 |
| Mr. Priyavrat Bhartia MBA | MD & Director | -- | -- | 1976 |
| Mr. Arjun Shanker Bhartia | Joint MD & Director | -- | -- | 1987 |
| Mr. Prakash Chandra Bisht B.Com., CA | Executive VP of Group Accounts | -- | -- | 1964 |
| Surajit Pal | Head of Investor Relations | -- | -- | -- |
| Mr. Sanjay Gupta A.C.M.A., B.Com., L.L.B. | Executive VP & Head of Legal | -- | -- | 1966 |
Jubilant Pharmova Limited
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 5,778
Description
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.
Corporate Governance
Recent Events
- Aug 10, 2023Ex-Dividend Date